The Biogen Inc., headquarters is shown in Cambridge, Mass. Medicare says it will limit coverage of a $28,200-per-year Alzheimer's drug whose benefits have been questioned. Steven Senne/AP hide caption toggle caption Steven Senne/AP Health Care Medicare proposes covering expensive Alzheimer's drug for those in clinical trials January 11, 2022 • Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.
